The 65-kDa heat-shock protein in the pathogenesis, prevention and therapy of autoimmune arthritis and diabetes mellitus in rats and mice.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 27 citations in OpenAlex.

1. HSP60: issues and insights on its therapeutic use as an immunoregulatory agent.Frontiers in immunology · 2011
   Article
2. Presence of hsp65 in bacterial extracts (OM-89): a possible mediator of orally-induced tolerance?Experientia · 1995
   Article
3. Hsp70: a carrier molecule with built-in adjuvanticity.Experientia · 1994
   Review
4. Hsp70--a multi-gene, multi-structure, multi-function family with potential clinical applications.Experientia · 1994
   Review
5. Heat shock proteins. Introduction.Experientia · 1992
   Review
6. Heat shock proteins in autoimmune disease. From causative antigen to specific therapy?Experientia · 1992
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as